Sinopharm Group Co. Ltd.

1099

CNE100000FN7

Pharmaceuticals

Market Closed - Hong Kong S.E. Other stock markets 04:08:24 2025-06-20 am EDT			5-day change	1st Jan Change
18.44 ^HKD	+0.88%		-3.96%	-13.43%

Jun. 12	Sinopharm Group Co. Ltd. Approves Board Appointments	CI
Jun. 10	Sinopharm Unit to Acquire 21% Stake in Pacific Shuanglin Bio-pharmacy	MT

China National Accord Medicines' Q1 Profit Slips 16%

Published on 04/24/2025 at 08:38, updated on 04/24/2025 at 08:46

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Sinopharm Group Co. Ltd.

Sinopharm Group Co. Ltd. Approves Board Appointments	Jun. 12	CI
Sinopharm Unit to Acquire 21% Stake in Pacific Shuanglin Bio-pharmacy	Jun. 10	MT
Sinopharm Group Appoints Hu Ligang As A Vice President	Jun. 09	RE
Sinopharm Group Co. Ltd Announces Resignation of Hu Ligang as Non-Executive Director, Effect from 9 June 2025	Jun. 09	CI
Sinopharm Group Co. Ltd. Announces Retirement of Mr. Li Dongjiu as Non-Executive Director, Member of the Audit Committee and A Member of the Strategy and Investment Committee, Effective May 16, 2025	May. 16	CI
Sinopharm's Q1 Profit Jumps	Apr. 28	MT
Sinopharm Group Co. Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2025	Apr. 28	CI
China National Accord Medicines' Q1 Profit Slips 16%	Apr. 24	MT
Sinopharm Group Posts Qtrly Net Profit Attributable RMB328 Million For Sinopharm Accord	Apr. 24	RE
Nomura Adjusts Sinopharm Group's Price Target to HK$23.40 From HK$25.09, Keeps at Buy	Mar. 25	MT
Sinopharm Group Co. Ltd. Reports Earnings Results for the Full Year Ended December 31, 2024	Mar. 23	CI
China National Accord Medicines' 2024 Profit Plunges 60%	Mar. 18	MT
Guizhou Xinbang Pharmaceutical's Subsidiary Involved in Bribery Lawsuit	Mar. 05	MT
Nomura Adjusts Sinopharm Group's Price Target to HK$25.09 From HK$28.46, Keeps at Buy	Feb. 27	MT
Sinopharm Group Co. Ltd. Approves Board Appointments	Feb. 12	CI
Sinopharm Group's Subsidiary Expects Up to 65% Lower Attributable Profit for 2024	Jan. 20	MT
Sinopharm Group Co. Ltd. Announces Board Resignations	Jan. 08	CI
Jinhai Medical Technology's Unit Authorizes Sinopharm to Solely Distribute Medical Devices in China	Jan. 03	MT
Sinopharm Group Records Lower Attributable Profit for Nine Months to September	24-10-28	MT
Sinopharm Group Co. Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2024	24-10-27	CI
Sinopharm Group's Subsidiary Records 10% Lower Attributable Net Profit in Q3	24-10-23	MT
Nomura Adjusts Sinopharm Group's Price Target to HK$28.46 From HK$30.33, Keeps at Buy	24-10-18	MT
Sinopharm Group's H1 Profit Declines 10% as Revenue Drops	24-09-24	MT
Shyndec Pharmaceutical's Chairman, President Resign	24-08-28	MT
Sinopharm Group Co. Ltd. Announces Change in President	24-08-27	CI

Chart Sinopharm Group Co. Ltd.

Duration

Period

1099: Dynamic Chart

Sinopharm Group Co Ltd is a China-based company principally engaged in pharmaceutical and medical devices distribution business.The Company operates its business through four segments. The Pharmaceutical Distribution segment provides distribution, logistics and other value-added services to domestic and foreign pharmaceutical and health product manufacturers and other suppliers. The Device Distribution segment distributes medical devices to customers. The Pharmaceutical Retail Business segment owns a network of retail pharmacies that are directly operated or franchised. The Other Business segment is engaged in the manufacture and sale of pharmaceuticals, chemical reagents and laboratory supplies.

Employees

108,217

Sector

Pharmaceuticals

Calendar

Aug. 31 - Q2 2025 Earnings Release (Projected)

More about the company